Gene editing company CRISPR Therapeutics AG is making significant strides in the development of gene-based medicines for a wide range of serious diseases by leveraging its highly innovative Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. CRISPR/Cas9 is a sophisticated gene editing technology that enables precise, directed changes to genomic DNA. The company boasts a diverse therapeutic portfolio across various disease areas, such as regenerative medicine, hemoglobinopathies, oncology, and rare diseases. Its flagship product candidate is CTX001, an ex vivo CRISPR gene editing therapy that triggers the production of high levels of fetal hemoglobin in red blood cells for patients with transfusion-dependent beta-thalassemia or severe sickle cell disease. CRISPR Therapeutics AG's broad pipeline includes CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy designed to target cluster of differentiation 19, CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen to treat relapsed or refractory multiple myeloma, and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy aimed at Cluster of Differentiation 70 to tackle hematologic malignancies and various solid tumors. Additionally, it is working on VCTX210, a groundbreaking gene-edited immune-evasive stem cell-derived product candidate that could potentially revolutionize the treatment of type 1 diabetes, and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived therapy to treat T1D. The company has entered into strategic partnerships with industry heavyweights like Bayer Healthcare, Vertex Pharmaceuticals, ViaCyte, Nkarta, and Capsida Biotherapeutics. Established in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics AG has emerged as a key player in the gene editing space, raising hopes for patients and investors alike.